CVRx Inc. Common Stock (CVRX)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am a value investor, so I start with owner earnings and a margin of safety. CVRx sells Barostim, an implantable neuromodulation device, and in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $15.7M while net income was -$14.0M. That is not a stable business yet. Full-year filed figures show FY2025 revenue of $56.7M and net loss of $53.3M, FY2024 revenue of $51.3M and net loss of $60.0M, and FY2023 revenue of $39.3M and net loss of $41.2M. Revenue is growing, but losses are enormous and persistent. Trailing free cash flow was -$41.1M against a $36.2M market cap at the 2026-10-13 close, so FairStock's FCF yield is -113.3%. At that close, the price was $1.36, and FairStock calculates a P/E of -0.69 and P/B of 1.81. The balance sheet looks strained: debt-to-equity is 2.98, ROE is -133.45%, ROCE is -28.70%, and Altman Z-score is -8.35, all FairStock calculations. Piotroski is 3/9, FairStock score is 21/100, and the Lynch category is none because of losses in each of the last four years. The 52-week range is $1.35 to $11.30. A medical device can have a moat if reimbursement and clinical adoption compound, but here the evidence is unproven. At $1.36, the price may reflect speculation, not a Graham margin of safety. I would need profits, cash generation, and a stronger balance sheet before calling it a sound value.

In plain English: CVRx makes an implanted device called Barostim to treat certain heart and blood pressure conditions. The company is selling more of it, but it still loses a lot of money and burns through cash; it has lost money for at least four years. At $1.36, the price looks very risky rather than clearly cheap based on its losses and cash use.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer